Skip to main content

Table 3 Neisseria gonorrhoeae isolates in Euro-GASP from 2009 to 2016 by anatomical site of infection, and resistance combined with decreased susceptibility to ceftriaxone, and resistance to cefixime, azithromycin, and ciprofloxacin

From: Associations between antimicrobial susceptibility/resistance of Neisseria gonorrhoeae isolates in European Union/European Economic Area and patients’ gender, sexual orientation and anatomical site of infection, 2009–2016

Site of infection

Ceftriaxone

Cefixime

Azithromycin

Ciprofloxacin

No of tested

DS No (%)

R No (%)

No of tested

R No (%)

No of tested

R No (%)

No of tested

R No (%)

Urogenital

12,113

1264 (10.4)

17 (0.1)

12,063

575 (4.8)

12,062

872 (7.2)

12,102

6508 (53.8)

 Female

2154

185 (8.6)

0 (0.0)

2154

96 (4.5)

2153

117 (5.4)

2153

993 (46.1)

 Males_Hetero

3343

415 (12.4)

5 (0.1)

3307

196 (5.9)

3302

284 (8.6)

3343

1921 (57.5)

 Males_MSM

1928

172 (8.9)

0 (0.0)

1917

57 (3.0)

1921

134 (7.0)

1926

900 (46.7)

 Males_Other/UNK

4621

485 (10.5)

12 (0.3)

4618

222 (4.8)

4619

334 (7.2)

4613

2653 (57.5)

 Unknown

67

7

0

67

4

67

3

67

41

Anorectal

1822

149 (8.2)

1 (0.1)

1822

35 (1.9)

1822

118 (6.5)

1822

774 (42.5)

 Female

113

15 (13.3)

0 (0.0)

113

9 (8.0)

113

10 (8.9)

113

61 (54.0)

 Males_Hetero

23

4 (17.4)

0 (0.0)

23

1 (4.4)

23

3 (13.0)

23

10 (43.5)

 Males_MSM

1357

99 (7.3)

1 (0.1)

1357

18 (1.3)

1357

78 (5.8)

1357

556 (41.0)

 Males_Other/UNK

316

29 (9.2)

0 (0.0)

316

6 (1.9)

316

26 (8.2)

316

140 (44.3)

 Unknown

13

2

0

13

1

13

1

13

7

Pharyngeal

883

72 (8.2)

2 (0.2)

883

22 (2.5)

883

73 (8.3)

883

365 (41.3)

 Female

134

20 (14.9)

0 (0.0)

134

10 (7.5)

134

14 (10.5)

134

66 (49.3)

 Males_Hetero

26

2 (7.7)

0 (0.0)

26

2 (7.7)

26

0 (0.0)

26

16 (61.5)

 Males_MSM

542

25 (4.6)

1 (0.2)

542

6 (1.1)

542

43 (7.9)

542

202 (37.3)

 Males_Other/UNK

175

24 (13.7)

0 (0.0)

175

1 (0.6)

175

13 (7.4)

175

78 (44.6)

 Unknown

6

1

1

6

3

6

3

6

3

Other

372

22 (5.9)

0 (0.0)

372

13 (3.5)

372

22 (5.9)

372

187 (50.3)

 Female

41

3 (7.3)

0 (0.0)

41

1 (2.4)

41

1 (2.4)

41

16 (39.0)

 Males_Hetero

40

5 (12.5)

0 (0.0)

40

4 (10.0)

40

2 (5.0)

40

26 (65.0)

 Males_MSM

26

0 (0.0)

0 (0.0)

26

0 (0.0)

26

0 (0.0)

26

11 (42.3)

 Males_Other/UNK

263

14 (5.3)

0 (0.0)

263

8 (3.0)

263

19 (7.2)

263

134 (51.0)

 Unknown

2

0

0

2

0

2

0

2

0

Unknown

613

76 (12.4)

6 (1.0)

611

27 (4.4)

613

33 (5.4)

613

323 (52.7)

 Female

94

9 (9.6)

0 (0.0)

93

1 (1.1)

94

1 (1.1)

94

45 (47.9)

 Males_Hetero

32

7 (21.9)

0 (0.0)

32

3 (9.4)

32

3 (9.4)

32

17 (53.1)

 Males_MSM

86

1 (1.2)

0 (0.0)

86

1 (1.2)

86

2 (2.3)

86

31 (36.1)

 Males_Other/UNK

305

35 (11.5)

1 (0.3)

304

10 (3.3)

305

23 (7.5)

305

172 (56.4)

 Unknown

96

24

5

96

12

96

4

96

58

Total

15,803

1583 (10.0)

26 (0.2)

15,751

672 (4.3)

15,752

1118 (7.1)

15,792

8157 (51.7)

  1. No Number, R Resistance, DS Decreased susceptibility, UNK Unknown sexual orientation